Insulin Sensitivity After Breast Cancer
Launched by UNIVERSITY OF COPENHAGEN · Aug 10, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how insulin sensitivity (the body’s ability to use insulin effectively) is affected in women who have survived breast cancer. Studies show that many women with breast cancer can develop metabolic disorders, which are conditions similar to type 2 diabetes. These disorders can lead to weight gain, high insulin levels, and problems with blood sugar, which may increase the risk of breast cancer coming back. The goal of this study is to understand how these metabolic issues occur in the muscles of breast cancer survivors and to identify any changes caused by cancer or its treatment.
To participate in this trial, women must be premenopausal, have undergone surgery for breast cancer, and completed their chemotherapy at least three weeks prior. They should also have a body mass index (BMI) between 25 and 30, which indicates being slightly overweight. The study will also include healthy women who match the participants in terms of age, weight, and activity level. Participants can expect to undergo tests to assess their insulin sensitivity and muscle health. It’s important to note that women who are postmenopausal, smoke, drink heavily, or have existing health issues like diabetes or heart disease will not be eligible for this study.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Premenopausal women operated for breast cancer and after completing adjuvant chemotherapy and no earlier than 3 weeks after its termination
- • BMI: 25-30
- • Healthy controls will be included matched by gender, weight, age, and level of physical activity to the patient group included as subjects
- Exclusion Criteria:
- • Known postmenopause occurred at the time of diagnosis of breast cancer
- • Alcohol intake of\> 7 items / week
- • Smoker
- • Already known Type 2 diabetes mellitus or metabolic syndrome and medical treatment thereof.
- • Cardiovascular disease and its medical treatment
- • Impaired mobility
About University Of Copenhagen
The University of Copenhagen, a leading research institution in Denmark, is dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including health sciences, pharmacology, and biotechnology, to design and conduct rigorous clinical studies. Committed to ethical standards and scientific integrity, the University of Copenhagen aims to contribute significantly to the global medical community by facilitating groundbreaking research that addresses pressing healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, Dk, Denmark
Patients applied
Trial Officials
Lykke Sylow, PhD
Principal Investigator
University of Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials